A Phase IIIb Parallel Group, Open Label Study of Pegylated Interferon Alfa-2a Monotherapy (PEG-IFN, Ro 25-8310) Compared to Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
Latest Information Update: 20 Nov 2022
Price :
$35 *
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms PEARL; Peg-B-Active
- Sponsors Roche
- 15 Dec 2021 Status changed from active, no longer recruiting to completed.
- 15 Jul 2021 This trial has been completed in Bulgaria, according to European Clinical Trials Database record.
- 09 Mar 2021 This trial has been completed in Belgium, according to European Clinical Trials Database record.